Cargando…
Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer
OBJECTIVE: The aim of this study is to determine the outcome of trastuzumab therapy for 6 or 12 months in patients with HER2 positive operable breast cancer who followed the national health insurance system in Indonesia. METHODS: Data were extracted from medical records of Dr. M Djamil General Hospi...
Autores principales: | Harahap, Wirsma Arif, Ramadhan, Khambri, Daan, Haryono, Samuel, Nindrea, Ricvan Dana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494230/ https://www.ncbi.nlm.nih.gov/pubmed/28548467 http://dx.doi.org/10.22034/APJCP.2017.18.4.1151 |
Ejemplares similares
-
Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis
por: Harahap, Wirsma Arif, et al.
Publicado: (2019) -
BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia
por: Harahap, Wirsma Arif, et al.
Publicado: (2018) -
Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis
por: Nindrea, Ricvan Dana, et al.
Publicado: (2018) -
The Prognostic Significance of Phosphatase and Tensin Homolog Loss in Breast Cancer
por: Windarti, Indri, et al.
Publicado: (2019) -
Survey data of COVID-19 awareness, knowledge, preparedness and related behaviors among breast cancer patients in Indonesia
por: Nindrea, Ricvan Dana, et al.
Publicado: (2020)